Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Change in Working Capital · Q3 FY2026 · quarter ended Aug 2026

Change in working capital grows, but more slowly than its trailing trend

Q3 FY2026 change in working capital of $52.37M rose 218.2% year over year, behind the +271.7% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +18.4% a year.

Context

  • Change in working capital amounted to 37.6% of revenue in FY2025, up 3.9 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +218.2% toward the trailing-twelve-month pace of +271.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterAug 2026
$52.37M+1443.6% QoQ
Last fiscal yearNov 2025
-$31.6M+71.7% YoY
LTMAug 2026
$50.82M+271.7% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+218.2%——
1 year+71.7%——
3-year CAGR+18.4%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(31.6M) USD
Year-over-year change
-71.7%

Change in Working Capital vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 change in working capital of $50.82M is the 4th largest of the 8 companies compared; the peer median is $2.13M.
  • Its year-over-year change of +271.7% is the highest of 8, against a peer median of -40.1%.
  • Change in working capital amounts to 7.2% of revenue for NRIX, versus a peer median of 37.3%.
NRIX Competitors Peer median
Change in Working Capital for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$158.92M -40.1%—221.8%
RVMDRevolution Medicines, Inc.LTM Jun 2026$86.82M +60.6%——
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$80.94M -757.4%—37.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$50.82M +271.7%+18.4%7.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$23.74M +149.1%+20.4%68.1%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.38M -10.5%-12.4%4.1%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$2.13M -90.0%—2.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.38M -98.2%+53.7%—
Peer median (excluding NRIX) $2.13M-40.1%+20.4%37.3%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
Deferred Income Tax00000
Stock-Based Compensation15.8M28.13M33.67M33.93M37.97M
Change in Working Capital9.11M(19.02M)20.12M(18.4M)(31.6M)
Accounts Receivables(6M)6M000
Inventory6.77M0000
Accounts Payables1.59M85K1.61M5.21M(630K)
Other Working Capital6.75M(25.11M)18.51M(23.61M)(30.97M)
Other Non-Cash Items1.83M636K(4.87M)(10.97M)(10.23M)
Operating Cash Flow(84.37M)(159.81M)(81.37M)(172.58M)(249.47M)
Capital Expenditures(5.66M)(12.24M)(8.4M)(9.27M)(14M)
Acquisitions (Net)102.59M(39.44M)000
Purchases of Investments(348.5M)(239.37M)(246.33M)(707.95M)(455.69M)
Sales of Investments245.91M278.81M323.04M459.51M617.54M
Other Investing Activities(102.59M)39.44M000
Investing Cash Flow(108.25M)27.2M68.3M(257.71M)147.85M
Debt Repayment00000
Common Stock Issued150.16M19.4M3.22M478.5M238.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.73M97.79M07.17M0
Financing Cash Flow153.88M117.19M3.22M485.67M238.64M
Effect of Forex Changes0000(67K)
Net Change in Cash(38.73M)(15.42M)(9.85M)55.37M137.03M
Free Cash Flow(90.03M)(172.05M)(89.77M)(181.86M)(263.47M)

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.